ASPC Congress on CVD Prevention to Take Place in July

Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.

On this episode of Managed Care Cast, we're talking with the chief science officer of the Center for Innovation & Value Research about key insights from its Rare Disease project.

Of the 518 hospitals that had at least 10 eligible discharges, only 11 of them prescribed SGLT2 inhibitors to more than half of their patients.

September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.

The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse events in patients less at risk of cardiomyopathy.

Follow-up results for the FINEARTS-HF trial focused on specific results for women and men, hyperkalemia risk, and an analysis of the elements of its composite end point.